Navigation Links
EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
Date:11/10/2008

Phase 2 Randomized Study Under Consideration

ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has met the primary endpoint for the efficacy portion of the open label Phase 1/2 study of MKC-1 in combination with pemetrexed (Alimta(R)) in non-small cell lung cancer patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Phase 1/2 study was designed to first evaluate a dose of MKC-1 to be used safely in combination with Alimta(R) to treat patients with advanced NSCLC. Patients were subsequently enrolled into the Phase 2 portion where the primary endpoint was tumor response. The primary endpoint has been met and EntreMed is considering options for further studies in NSCLC patients. Options include the continuation of the current single arm study or a randomized Phase 2 study in the same patient population.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models.

MKC-1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase (mitosis) of the cell cycle, and induce apoptosis. Furthermore, MKC-1 inhibits the Akt-mTOR signaling pathways, which may occur through inh
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
2. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... results before the Nasdaq market opens on Thursday, April ... and webcast to discuss its financial results and provide ... 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... dialing 866-952-1906 (US) or 785-424-1825 (International) using the conference ...
(Date:4/23/2015)... LONDON , April 23, 2015 ... Medical Equipment   Report Details   ... reach a value of $101.3 billion in 2015 and will ... Strong growth in the healthcare sectors around the world and ... the key growth factors in the global healthcare packaging ...
(Date:4/23/2015)... 23, 2015 /PRNewswire/ - Crystal Research Associates, LLC announced ... ® (EIO) on Aeterna Zentaris Inc. (NASDAQ: ... on Crystal Research Associates, website at www.crystalra.com ... at www.aezsinc.com . Aeterna Zentaris ("Aeterna" ... company in oncology, endocrinology, and women,s health. With a ...
(Date:4/22/2015)... MN , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and ... for the first quarter 2015 on Thursday, May 7, ... has scheduled a webcast and conference call for 4.30 ... Live audio of the conference call ... available to investors, members of the news media and ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2
... whose MBA and undergraduate degree were minted at the ... Clear Software's North American operations, the company said on ... ,Cape Clear, headquartered in Massachusetts, provides "enterprise service bus" ... State of Wisconsin Department of Administraiton. , ,Though its ...
... are interested in bio and life science investments in ... Meanwhile the University of Wisconsin-Madison is introducing two new ... 30, 2005 Listen to this episode ... with companies in Madison ...
... Genzyme Corp. said on Wednesday it has agreed ... Wisconsin-Madison biotech spinoff, for $600 million in cash. , ,Bone ... more than $2 billion and almost 7,000 employees worldwide, plan ... companies recently reported healthy quarterly profits and revenues. Bone Care ...
Cached Biology Technology:Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Sweden and the University of Glasgow, Scotland, has identified a ... gastrointestinal bacteria. In a study published as a letter to ... suggesting that the human genome may play a role in ... human gastrointestinal tract collectively known as the gut microbiota. ...
... a classic example of evolutionary adaptation, with beaks that vary ... While living birds have a beak to manipulate their food, ... discovery shows some fossil birds evolved teeth adapted for specialized ... a new species of early bird, Sulcavis geeorum , ...
... by senior author Morris J. Birnbaum, MD, PhD, the ... Institute for Diabetes, Obesity, and Metabolism, Perelman School of ... metformin works in a different way than previously understood. ... liver hormone glucagon,s ability to generate an important signaling ...
Cached Biology News:International study suggests human genes influence gut microbial composition 2First fossil bird with teeth specialized for tough diet 2Most-used diabetes drug works in different way than previously thought 2
... of calcium binding proteins such as calmodulin and ... alpha and beta chain whereas S100B is composed ... also expressed in the antigen presenting cells such ... reticulum cells in the paracortex of lymph nodes. ...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Polyclonal Antibody to CLAN...
Biology Products: